WO2020021024A1 - Composés bicycliques substitués en tant que modulateurs du récepteur d'hydrocarbures aryle (ahr) - Google Patents
Composés bicycliques substitués en tant que modulateurs du récepteur d'hydrocarbures aryle (ahr) Download PDFInfo
- Publication number
- WO2020021024A1 WO2020021024A1 PCT/EP2019/070066 EP2019070066W WO2020021024A1 WO 2020021024 A1 WO2020021024 A1 WO 2020021024A1 EP 2019070066 W EP2019070066 W EP 2019070066W WO 2020021024 A1 WO2020021024 A1 WO 2020021024A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- independently selected
- halogen
- cycloalkyl
- substituted
- Prior art date
Links
- 0 *c1cc(C#N)ccc1C(F)(F)F Chemical compound *c1cc(C#N)ccc1C(F)(F)F 0.000 description 9
- QBDXSEYWEKKYSH-UHFFFAOYSA-N Cc1nnc[n]1C Chemical compound Cc1nnc[n]1C QBDXSEYWEKKYSH-UHFFFAOYSA-N 0.000 description 3
- GBEGSIQXJCMMPL-UHFFFAOYSA-N CC(C)c1cc(C#N)ccc1C(F)(F)F Chemical compound CC(C)c1cc(C#N)ccc1C(F)(F)F GBEGSIQXJCMMPL-UHFFFAOYSA-N 0.000 description 2
- ZLZHERXZBYAESX-UHFFFAOYSA-N CC(C)c1cc(Cl)ccc1C(F)(F)F Chemical compound CC(C)c1cc(Cl)ccc1C(F)(F)F ZLZHERXZBYAESX-UHFFFAOYSA-N 0.000 description 2
- PYMVEJHTLNXSBC-UHFFFAOYSA-N CC(C)c1cc(F)ccc1C(F)F Chemical compound CC(C)c1cc(F)ccc1C(F)F PYMVEJHTLNXSBC-UHFFFAOYSA-N 0.000 description 2
- WWRCMNKATXZARA-UHFFFAOYSA-N CC(C)c1ccccc1C Chemical compound CC(C)c1ccccc1C WWRCMNKATXZARA-UHFFFAOYSA-N 0.000 description 2
- LRMXTWCDIPSDCW-UHFFFAOYSA-N CC(C)c1ccccc1C(F)(F)F Chemical compound CC(C)c1ccccc1C(F)(F)F LRMXTWCDIPSDCW-UHFFFAOYSA-N 0.000 description 2
- FLPWYJGTTKUYRV-UHFFFAOYSA-N CCc1nnc[n]1C Chemical compound CCc1nnc[n]1C FLPWYJGTTKUYRV-UHFFFAOYSA-N 0.000 description 2
- CZELRRPZZUHEKP-UHFFFAOYSA-N CNC(c1nnc[n]1C)=O Chemical compound CNC(c1nnc[n]1C)=O CZELRRPZZUHEKP-UHFFFAOYSA-N 0.000 description 2
- LSZQMSSIUQNTDX-UHFFFAOYSA-N Cc1ccn[n]1C Chemical compound Cc1ccn[n]1C LSZQMSSIUQNTDX-UHFFFAOYSA-N 0.000 description 2
- CPFGLEUDGOVNGN-UHFFFAOYSA-N CC(C)(C)OC([n]1c2nc(Cl)ccc2cc1-c1ccccc1C(F)(F)F)=O Chemical compound CC(C)(C)OC([n]1c2nc(Cl)ccc2cc1-c1ccccc1C(F)(F)F)=O CPFGLEUDGOVNGN-UHFFFAOYSA-N 0.000 description 1
- DZJPCZYLXLSBFZ-UHFFFAOYSA-N CC(C)NC(c1ccn[n]1C)=O Chemical compound CC(C)NC(c1ccn[n]1C)=O DZJPCZYLXLSBFZ-UHFFFAOYSA-N 0.000 description 1
- OBWVNHHTCWDHFV-UHFFFAOYSA-N CC(C)NC(c1ncn[n]1C)=O Chemical compound CC(C)NC(c1ncn[n]1C)=O OBWVNHHTCWDHFV-UHFFFAOYSA-N 0.000 description 1
- STERQFIZWRUAIL-UHFFFAOYSA-N CC(C)c1ccccc1C(F)F Chemical compound CC(C)c1ccccc1C(F)F STERQFIZWRUAIL-UHFFFAOYSA-N 0.000 description 1
- RNEMUWDQJSRDMQ-UHFFFAOYSA-N CC(C)c1ccccc1Cl Chemical compound CC(C)c1ccccc1Cl RNEMUWDQJSRDMQ-UHFFFAOYSA-N 0.000 description 1
- LFBKXGCXEAAFAW-UHFFFAOYSA-N CC(NC(c1ncn[n]1C)=O)=C Chemical compound CC(NC(c1ncn[n]1C)=O)=C LFBKXGCXEAAFAW-UHFFFAOYSA-N 0.000 description 1
- OCOJWOQFNPHHCL-UHFFFAOYSA-N CC(Nc1nc([nH]c(-c2c(C(F)(F)F)cccc2)c2)c2[s]1)=O Chemical compound CC(Nc1nc([nH]c(-c2c(C(F)(F)F)cccc2)c2)c2[s]1)=O OCOJWOQFNPHHCL-UHFFFAOYSA-N 0.000 description 1
- HTBVWINTPKSUHR-UHFFFAOYSA-N CCc1ccccc1C(F)F Chemical compound CCc1ccccc1C(F)F HTBVWINTPKSUHR-UHFFFAOYSA-N 0.000 description 1
- HXXAUIXTYRHFNO-UHFFFAOYSA-N CNC(c1ccccn1)=O Chemical compound CNC(c1ccccn1)=O HXXAUIXTYRHFNO-UHFFFAOYSA-N 0.000 description 1
- IEQPYEHIGOWSDR-UHFFFAOYSA-N CS(N(c1nc(Cl)ccc1I)S(C)(=O)=O)(=O)=O Chemical compound CS(N(c1nc(Cl)ccc1I)S(C)(=O)=O)(=O)=O IEQPYEHIGOWSDR-UHFFFAOYSA-N 0.000 description 1
- XRWUZWCCAJDRTC-UHFFFAOYSA-N C[n]1ncnc1C(Nc1nc([nH]c(-c2c(C(F)(F)F)cccc2)c2)c2[s]1)=O Chemical compound C[n]1ncnc1C(Nc1nc([nH]c(-c2c(C(F)(F)F)cccc2)c2)c2[s]1)=O XRWUZWCCAJDRTC-UHFFFAOYSA-N 0.000 description 1
- FRAKGJKEMLMXMD-UHFFFAOYSA-N Cc1ncn[n]1C Chemical compound Cc1ncn[n]1C FRAKGJKEMLMXMD-UHFFFAOYSA-N 0.000 description 1
- CEOBHQXPEQZKBH-UHFFFAOYSA-N FC(c1ccccc1-c([nH]c1n2)cc1ccc2Cl)(F)F Chemical compound FC(c1ccccc1-c([nH]c1n2)cc1ccc2Cl)(F)F CEOBHQXPEQZKBH-UHFFFAOYSA-N 0.000 description 1
- GGXIOSCUHASSOL-UHFFFAOYSA-N Nc(nc(cc1)Cl)c1I Chemical compound Nc(nc(cc1)Cl)c1I GGXIOSCUHASSOL-UHFFFAOYSA-N 0.000 description 1
- WBZGDALZODGRDI-UHFFFAOYSA-N Nc1nc([nH]c(-c2c(C(F)(F)F)cccc2)c2)c2[s]1 Chemical compound Nc1nc([nH]c(-c2c(C(F)(F)F)cccc2)c2)c2[s]1 WBZGDALZODGRDI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
La présente invention concerne des composés bicycliques qui peuvent agir en tant que modulateurs du récepteur d'hydrocarbures aryle (AhR) et, en particulier, en tant qu'antagonistes d'AhR. L'invention concerne en outre l'utilisation des composés pour le traitement et/ou la prophylaxie de maladies et/ou d'états par liaison dudit récepteur d'hydrocarbure aryle par lesdits composés. A-B-L-C (I)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18185817 | 2018-07-26 | ||
EP18185817.6 | 2018-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020021024A1 true WO2020021024A1 (fr) | 2020-01-30 |
Family
ID=63207518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2019/070066 WO2020021024A1 (fr) | 2018-07-26 | 2019-07-25 | Composés bicycliques substitués en tant que modulateurs du récepteur d'hydrocarbures aryle (ahr) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020021024A1 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020201825A2 (fr) | 2019-03-29 | 2020-10-08 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Signature d'activation de récepteur d'hydrocarbures aryliques (ahr) et procédés de détermination d'état de signalisation d'ahr |
WO2020208190A1 (fr) | 2019-04-10 | 2020-10-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Gène 1 induit par l'interleukine 4 (il4i1) en tant que biomarqueur et ses utilisations |
WO2021116357A1 (fr) | 2019-12-10 | 2021-06-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Gène 1 induit par l'interleukine 4 (il4i1) et métabolites respectifs en tant que biomarqueurs pour le cancer |
WO2021173082A1 (fr) | 2020-02-26 | 2021-09-02 | Jaguahr Therapeutics Pte Ltd | Dérivés de pyridopyrimidine utiles dans la modulation de la signalisation de l'ahr |
WO2021242955A1 (fr) * | 2020-05-28 | 2021-12-02 | Senda Biosciences, Inc. | Hétérocycles azolés fusionnés utilisés en tant qu'antagonistes d'ahr |
CN113831320A (zh) * | 2020-06-23 | 2021-12-24 | 上海美悦生物科技发展有限公司 | 一种稠和吡唑类化合物的制备方法 |
CN114456178A (zh) * | 2021-01-13 | 2022-05-10 | 重庆华森制药股份有限公司 | 四氢嘧啶[1,2-b]吲唑-4-胺类衍生物作为AhR抑制剂的用途及制备方法 |
CN115572282A (zh) * | 2021-07-05 | 2023-01-06 | 华东理工大学 | 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用 |
US11767321B2 (en) | 2020-10-05 | 2023-09-26 | Enliven Inc. | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases |
WO2024076300A1 (fr) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Composés utiles dans la modulation de la signalisation d'ahr |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012076430A1 (fr) * | 2010-12-07 | 2012-06-14 | F. Hoffmann-La Roche Ag | Composés de triazolopyridine |
US20130338201A1 (en) * | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
WO2014100620A2 (fr) * | 2012-12-21 | 2014-06-26 | Plexxikon Inc. | Composés et procédés pour la modulation de kinase, et indications associées |
WO2014177493A1 (fr) * | 2013-04-30 | 2014-11-06 | F. Hoffmann-La Roche Ag | Couplage de pyrazole-amides catalysé par pd |
US20160175278A1 (en) | 2010-07-27 | 2016-06-23 | Trustees Of Boston University | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS |
WO2018141855A1 (fr) * | 2017-02-01 | 2018-08-09 | Phenex Pharmaceuticals Ag | Composés modulateurs du récepteur des hydrocarbures d'aryl (ahr) |
WO2018141857A1 (fr) * | 2017-02-01 | 2018-08-09 | Phenex Pharmaceuticals Ag | Composés modulateurs du récepteur des hydrocarbures d'aryl (ahr) |
WO2018153893A1 (fr) * | 2017-02-21 | 2018-08-30 | Phenex Pharmaceuticals Ag | Composés modulateurs du récepteur des hydrocarbures aryle (ahr) |
-
2019
- 2019-07-25 WO PCT/EP2019/070066 patent/WO2020021024A1/fr active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130338201A1 (en) * | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
US20160175278A1 (en) | 2010-07-27 | 2016-06-23 | Trustees Of Boston University | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS |
WO2012076430A1 (fr) * | 2010-12-07 | 2012-06-14 | F. Hoffmann-La Roche Ag | Composés de triazolopyridine |
WO2014100620A2 (fr) * | 2012-12-21 | 2014-06-26 | Plexxikon Inc. | Composés et procédés pour la modulation de kinase, et indications associées |
WO2014177493A1 (fr) * | 2013-04-30 | 2014-11-06 | F. Hoffmann-La Roche Ag | Couplage de pyrazole-amides catalysé par pd |
WO2018141855A1 (fr) * | 2017-02-01 | 2018-08-09 | Phenex Pharmaceuticals Ag | Composés modulateurs du récepteur des hydrocarbures d'aryl (ahr) |
WO2018141857A1 (fr) * | 2017-02-01 | 2018-08-09 | Phenex Pharmaceuticals Ag | Composés modulateurs du récepteur des hydrocarbures d'aryl (ahr) |
WO2018153893A1 (fr) * | 2017-02-21 | 2018-08-30 | Phenex Pharmaceuticals Ag | Composés modulateurs du récepteur des hydrocarbures aryle (ahr) |
Non-Patent Citations (8)
Title |
---|
BESSEDE ET AL., NATURE, vol. 511, no. 7508, 10 July 2014 (2014-07-10), pages 184 - 90 |
KOLIOPANOS ET AL., ONCOGENE, vol. 21, no. 39, 5 September 2002 (2002-09-05), pages 6059 - 70 |
LI ET AL., INT J CLIN EXP PATHOL., vol. 7, no. 11, 15 October 2014 (2014-10-15), pages 7931 |
MURRAY ET AL., NAT REV CANCER, vol. 14, no. 12, December 2014 (2014-12-01), pages 801 - 14 |
RICHMOND ET AL., PLOS ONE, vol. 9, no. 4, 2014, pages e95058 |
ROMANI ET AL., EUR J IMMUNOL., vol. 44, no. 11, November 2014 (2014-11-01), pages 3192 - 200 |
SAFE ET AL., TOXICOL SCI., vol. 135, no. 1, September 2013 (2013-09-01), pages 1 - 16 |
ZELANTE ET AL., IMMUNITY, vol. 39, no. 2, 22 August 2013 (2013-08-22), pages 372 - 85 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020201825A2 (fr) | 2019-03-29 | 2020-10-08 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Signature d'activation de récepteur d'hydrocarbures aryliques (ahr) et procédés de détermination d'état de signalisation d'ahr |
WO2020208190A1 (fr) | 2019-04-10 | 2020-10-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Gène 1 induit par l'interleukine 4 (il4i1) en tant que biomarqueur et ses utilisations |
WO2021116357A1 (fr) | 2019-12-10 | 2021-06-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Gène 1 induit par l'interleukine 4 (il4i1) et métabolites respectifs en tant que biomarqueurs pour le cancer |
WO2021173082A1 (fr) | 2020-02-26 | 2021-09-02 | Jaguahr Therapeutics Pte Ltd | Dérivés de pyridopyrimidine utiles dans la modulation de la signalisation de l'ahr |
WO2021242955A1 (fr) * | 2020-05-28 | 2021-12-02 | Senda Biosciences, Inc. | Hétérocycles azolés fusionnés utilisés en tant qu'antagonistes d'ahr |
WO2021259163A1 (fr) * | 2020-06-23 | 2021-12-30 | 上海美悦生物科技发展有限公司 | Procédé de préparation d'un composé de type pyrazole condensé |
CN113831320A (zh) * | 2020-06-23 | 2021-12-24 | 上海美悦生物科技发展有限公司 | 一种稠和吡唑类化合物的制备方法 |
CN113831320B (zh) * | 2020-06-23 | 2024-04-05 | 上海美悦生物科技发展有限公司 | 一种稠和吡唑类化合物的制备方法 |
US11767321B2 (en) | 2020-10-05 | 2023-09-26 | Enliven Inc. | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases |
US11807638B2 (en) | 2020-10-05 | 2023-11-07 | Enliven Inc. | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases |
CN114456178A (zh) * | 2021-01-13 | 2022-05-10 | 重庆华森制药股份有限公司 | 四氢嘧啶[1,2-b]吲唑-4-胺类衍生物作为AhR抑制剂的用途及制备方法 |
CN115572282A (zh) * | 2021-07-05 | 2023-01-06 | 华东理工大学 | 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用 |
WO2024076300A1 (fr) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Composés utiles dans la modulation de la signalisation d'ahr |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020021024A1 (fr) | Composés bicycliques substitués en tant que modulateurs du récepteur d'hydrocarbures aryle (ahr) | |
AU2018216955B2 (en) | Aryl hydrocarbon receptor (AhR) modulator compounds | |
AU2018216957B2 (en) | Aryl hydrocarbon receptor (AhR) modulator compounds | |
EP3585780A1 (fr) | Composés modulateurs du récepteur des hydrocarbures aryle (ahr) | |
KR20180002748A (ko) | 아미도-치환된 시클로헥산 유도체 | |
EP3841102A1 (fr) | Dérivés de tétrahydropyridopyrimidine utilisés comme modulateurs du ahr | |
WO2016106266A1 (fr) | Antagonistes des récepteurs tgfβ | |
KR20220061958A (ko) | Cd38의 억제제로서의 헤테로바이사이클릭 아미드 | |
CN107207504B (zh) | 酞嗪酮衍生物、其制备方法及用途 | |
CA3230491A1 (fr) | Composes tricycliques substitues utilises en tant qu'inhibiteurs de parp et leur utilisation | |
JP2022551299A (ja) | Brd4阻害活性を有する化合物、その調製方法および用途 | |
WO2021148628A1 (fr) | Composés hétérocycliques substitués par un oxalamide en tant que modulateurs du récepteur d'aryle hydrocarbone (ahr) | |
WO2020116662A1 (fr) | Dérivé de cycloalcane-1,3-diamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19742768 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19742768 Country of ref document: EP Kind code of ref document: A1 |